Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity

DNA Repair

Volumn 12, Issue 12, 2013, Pages 1114-1121

  Ladd, Brendon ^a,b   Ackroyd, Jeffrey J ^a   Hicks, J Kevin ^a,c   Canman, Christine E ^a   Flanagan, Sheryl A ^a   Shewach, Donna S ^a  

^a Department of Pharmacology ^*  (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticancer drug; DNA damage; DNA repair; Histone deacetylase inhibitor; Homologous recombination

Indexed keywords

ABEXINOSTAT; GANCICLOVIR; HISTONE H2AX; RAD51 PROTEIN; VORINOSTAT;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; RECOMBINATION REPAIR;

SIMPLEXVIRUS;

ANTICANCER DRUG; DNA DAMAGE; DNA DOUBLE STRAND BREAK; DNA REPAIR; DR-GFP; DSB; GANCICLOVIR; GANCICLOVIR 5′-MONOPHOSPHATE; GANCICLOVIR 5′-TRIPHOSPHATE; GCV; GCVMP; GCVTP; GREEN FLUORESCENT PROTEIN RECOMBINATION SUBSTRATE; HDAC; HERPES SIMPLEX VIRUS THYMIDINE KINASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HOMOLOGOUS RECOMBINATION; HR; HSV-TK; LACZ; MISMATCH REPAIR; MMR; SAHA; SUBEROYLANILIDE HYDROXAMIC ACID; Β-GALACTOSIDASE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARRIER PROTEINS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETULUS; GANCICLOVIR; HELA CELLS; HOMOLOGOUS RECOMBINATION; HUMANS; HYDROXAMIC ACIDS; NUCLEAR PROTEINS; RAD51 RECOMBINASE;

EID: 84888132744     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2013.10.008     Document Type: Article

References (51)

1. Burnett A., Wetzler M., Lowenberg B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 2011, 29:487-494.
2. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
3. Azzoli C.G., Temin S., Aliff T., Baker S., Brahmer J., Johnson D.H., Laskin J.L., Masters G., Milton D., Nordquist L., Pao W., Pfister D.G., Piantadosi S., Schiller J.H., Smith R., Smith T.J., Strawn J.R., Trent D., Giaccone G. Focused update of 2009 American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 2011, 29:3825-3831.
4. Duarte S., Carle G., Faneca H., de Lima M.C., Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now?. Cancer Lett. 2012, 324:160-170.
5. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell Biol. 2001, 21:4129-4139.
6. Karnitz L.M., Flatten K.S., Wagner J.M., Loegering D., Hackbarth J.S., Arlander S.J., Vroman B.T., Thomas M.B., Baek Y.U., Hopkins K.M., Lieberman H.B., Chen J., Cliby W.A., Kaufmann S.H. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol. Pharmacol. 2005, 68:1636-1644.
7. Burma S., Chen B.P., Murphy M., Kurimasa A., Chen.F D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 2001, 276:42462-42467.
8. Cho S.H., Toouli C.D., Fujii G.H., Crain C., Parry D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 2005, 4:131-139.
9. Matthews D.J., Yakes F.M., Chen J., Tadano M., Bornheim L., Clary D.O., Tai A., Wagner J.M., Miller N., Kim Y.D., Robertson S., Murray L., Karnitz L.M. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 2007, 6:104-110.
10. Sampath D., Shi Z., Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol. Pharmacol. 2002, 62:680-688.
11. Karp J.E., Thomas B.M., Greer J.M., Sorge C., Gore S.D., Pratz K.W., Smith B.D., Flatten K.S., Peterson K., Schneider P., Mackey K., Freshwater T., Levis M.J., McDevitt M.A., Carraway H.E., Gladstone D.E., Showel M.M., Loechner S., Parry D.A., Horowitz J.A., Isaacs R., Kaufmann S.H. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin. Cancer Res. 2012, 18:6723-6731.
12. Hawn M.T., Umar A., Carethers J.M., Marra G., Kunkel T.A., Boland C.R., Koi.M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 1995, 55:3721-3725.
13. Fordham S.E., Matheson E.C., Scott K., Irving J.A., Allan J.M. DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs. Leukemia 2011, 25:1046-1049.
14. Moolten F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986, 46:5276-5281.
15. Rubsam L.Z., Davidson B.L., Shewach D.S. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-d-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res. 1998, 58:3873-3882.
16. Boucher P.D., Ostruszka L.J., Murphy P.J., Shewach D.S. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 2002, 9:1023-1030.
17. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 2000, 11:2389-2401.
18. Freytag S.O., Movsas B., Aref I., Stricker H., Peabody J., Pegg J., Zhang Y., Barton K.N., Brown S.L., Lu M., Savera A., Kim.J.H. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 2007, 15:1016-1023.
19. Thust R., Tomicic M., Klocking R., Voutilainen N., Wutzler P., Kaina B. Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches. Cancer Gene Ther. 2000, 7:107-117.
20. Tomicic M.T., Thust R., Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene 2002, 21:2141-2153.
21. Ladd B., O'Konek J.J., Ostruszka L.J., Shewach D.S. Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir. Cancer Gene Ther. 2011, 18:751-759.
22. Thust R., Schacke M., Wutzler P. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res. 1996, 31:105-113.
23. Wilson D.M., Thompson L.H. Molecular mechanisms of sister-chromatid exchange. Mutat. Res. 2007, 616:11-23.
24. Papouli E., Cejka P., Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 2004, 64:3391-3394.
25. O'Konek J.J., Boucher P.D., Iacco A.A., Wilson T.E., Shewach D.S. MLH1 deficiency enhances tumor cell sensitivity to ganciclovir. Cancer Gene Ther. 2009, 16:683-692.
26. Paques F., Haber J.E. Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 1999, 63:349-404.
27. Chinnaiyan P., Vallabhaneni G., Armstrong E., Huang S.M., Harari P.M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62:223-229.
28. Weinstock D.M., Nakanishi K., Helgadottir H.R., Jasin M. Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol. 2006, 409:524-540.
29. Boucher P.D., Im M.M., Freytag S.O., Shewach D.S. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res. 2006, 66:3230-3237.
30. Machado S.G., Robinson G.A. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat. Med. 1994, 13:2289-2309.
31. Kokoris M.S., Sabo P., Adman E.T., Black M.E. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. 1999, 6:1415-1426.
32. Pierce A.J., Johnson R.D., Thompson L.H., Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999, 13:2633-2638.
33. Sharma S., Hicks J.K., Chute C.L., Brennan J.R., Ahn J.Y., Glover T.W., Canman C.E. REV1 and polymerase zeta facilitate homologous recombination repair. Nucleic Acids Res. 2012, 40:682-691.
34. Fuller L.F., Painter R.B. A Chinese hamster ovary cell line hypersensitive to ionizing radiation and deficient in repair replication. Mutat. Res. 1988, 193:109-121.
35. Tebbs R.S., Zhao Y., Tucker J.D., Scheerer J.B., Siciliano M.J., Hwang M., Liu N., Legerski R.J., Thompson L.H. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:6354-6358.
36. Chen X., Wong P., Radany E.H., Stark J.M., Laulier C., Wong.J.Y. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol. Cancer Res. 2012, 10:1052-1064.
37. Adimoolam S., Sirisawad M., Chen J., Thiemann P., Ford J.M., Buggy J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19482-19487.
38. Ammerpohl O., Thormeyer D., Khan Z., Appelskog I.B., Gojkovic Z., Almqvist P.M., Ekstrom T.J. HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem. Biophys. Res. Commun. 2004, 324:8-14.
39. Sartori A.A., Lukas C., Coates J., Mistrik M., Fu S., Bartek J., Baer R., Lukas J., Jackson S.P. Human CtIP promotes DNA end resection. Nature 2007, 450:509-514.
40. Wyman C., Ristic D., Kanaar R. Homologous recombination-mediated double-strand break repair. DNA Repair (Amst.) 2004, 3:827-833.
41. Premkumar D.R., Jane E.P., Agostino N.R., Didomenico J.D., Pollack I.F. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol. Carcinog. 2013, 52:118-133.
42. Yamamoto S., Yamano T., Tanaka M., Hoon D.S., Takao S., Morishita R., Aikou T., Kaneda Y. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther. 2003, 10:179-186.
43. Kothari V., Joshi G., Nama S., Somasundaram K., Mulherkar R. HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model. Int. J. Cancer 2010, 126:733-742.
44. Ryu C.H., Park K.Y., Kim S.M., Jeong C.H., Woo J.S., Hou Y., Jeun.S.S. Valproic acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK gene therapy in intracranial glioma. Biochem. Biophys. Res. Commun. 2012, 421:585-590.
45. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27:5459-5468.
46. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10833-10838.
47. Gospodinov A., Popova S., Vassileva I., Anachkova B. The inhibitor of histone deacetylases sodium butyrate enhances the cytotoxicity of mitomycin C. Mol. Cancer Ther. 2012, 11:2116-2126.
48. Liu X., Wang Y., Benaissa S., Matsuda A., Kantarjian H., Estrov Z., Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood 2010, 116:1737-1746.
49. Foti M., Marshalko S., Schurter E., Kumar S., Beardsley G.P., Schweitzer B.I. Solution structure of a DNA decamer containing the antiviral drug ganciclovir: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. Biochemistry 1997, 36:5336-5345.
50. Lee J.H., Choy M.L., Ngo L., Foster S.S., Marks P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14639-14644.
51. Rangwala S., Zhang C.L., Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med. Chem. 2012, 4:471-486.